An ADR pharmaceutical care for severe gastrointestinal bleeding of rivaroxaban in a patient with nonvalvular atrial fibrillation based on TDM and genetic testing: a case report
Abstract Background Due to its predictable pharmacodynamics and pharmacokinetics, stable blood concentration, and relatively short half-life, rivaroxaban is widely used in the prevention and treatment of thrombosis. It nevertheless exhibits a certain level of inter-individual variability, and its sa...
Sparad:
| Huvudupphov: | , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
BMC
2025-10-01
|
| Serie: | BMC Medical Genomics |
| Ämnen: | |
| Länkar: | https://doi.org/10.1186/s12920-025-02222-4 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|